Enzymopenic hereditary methemoglobinemia.
The normal erythrocyte is well endowed with a system to convert useless methemoglobin to functional hemoglobin. The major mechanism for this reductive capacity resides in the soluble cytochrome b5/NADH cytochrome b5 reductase of the cytosol which presumably arise from the microsomal proteins of the endoplasmic reticulum through proteolytic cleavage of the proteins' hydrophobic tails during the maturation of nucleated erythrocyte precursors. NADH cytochrome b5 reductase is coded for by a gene on the human chromosome 22. Inheritance of a pair of abnormal alleles which specify an enzyme with decreased activity or stability occurs only rarely, but leads to enzymopenic hereditary methemoglobinemia. Type I, uncomplicated, benign methemoglobinemia is attributed to mutation in paired alleles that affect primarily the catalytic capacity, stability, or solubilization of the polar, soluble segment of the enzyme. It does not appear to affect significantly the well being or life expectancy of the homozygous subject. The cosmetic affliction or the minimal symptoms can rather easily be controlled with methylene blue, ascorbic acid, or riboflavin. The heterozygote is entirely asymptomatic, but may have an increased tendency to develop methemoglobinemia on exposure to methemoglobin-inducing drugs or chemicals. Type II, severe lethal methemoglobinemia is a generalized disorder in which the NADH cytochrome b5 reductase is apparently defective in all tissues. It is thought to result from either gene deletion or mutation in paired alleles that determine the function, stability, or attachment to the endoplasmic reticulum of the entire enzyme, both the polar and the hydrophobic segments. As in Type I, the heterozygote is asymptomatic, and the homozygote's methemoglobinemia is readily controlled. The generalized disorder including the neurologic dysfunction, however, is not amenable to treatment at this time. Prenatal diagnosis by examination of amniotic fluid cells is both feasible and useful.